Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 14/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 12/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 7/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 4/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13471220 | 0.84 | SLC2A1 (0.47) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL13274634 | 0.82 | S1PR3 (0.65) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL13469327 | 0.80 | S1PR1 (0.40) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL13469236 | 0.80 | S1PR1 (0.40) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL13464647 | 0.79 | S1PR1 (0.39) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL13464618 | 0.79 | S1PR1 (0.39) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL17213912 | 0.77 | KDM4E (0.39) | S1PR1S1PR3S1PR5 | |
| SCHEMBL17060880 | 0.76 | SLC2A1 (0.46) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14642772 | 0.73 | S1PR3 (0.40) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL17214346 | 0.72 | SCN8A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946195-B2 | Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140206652-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716267-B2 | Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120264718-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142377-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206652-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR2 3/4885 |
| US-20120264718-A1 | BICYCLIC METHYL AMINE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.